Literature DB >> 28258794

Brain bioenergetics and redox state measured by 31P magnetic resonance spectroscopy in unaffected siblings of patients with psychotic disorders.

Virginie-Anne Chouinard1, Sang-Young Kim2, Linda Valeri3, Cagri Yuksel2, Kyle P Ryan4, Guy Chouinard5, Bruce M Cohen2, Fei Du2, Dost Öngür2.   

Abstract

BACKGROUND: Brain bioenergetic anomalies and redox dysregulation have been implicated in the pathophysiology of psychotic disorders. The present study examined brain energy-related metabolites and the balance between nicotinamide adenine dinucleotide metabolites (oxidized NAD+ and reduced NADH) using 31P-magnetic resonance spectroscopy (31P-MRS) in unaffected siblings, compared to first episode psychosis (FEP) patients and healthy controls.
METHODS: 21 unaffected siblings, 32 FEP patients (including schizophrenia spectrum and affective psychoses), and 21 controls underwent 31P-MRS in the frontal lobe (6×6×4cm3) on a 4T MR scanner, using custom-designed dual-tuned surface coil with outer volume suppression. Brain parenchymal pH and steady-state metabolite ratios of high energy phosphate compounds were measured. NAD+ and NADH levels were determined using a 31P-MRS fitting algorithm. 13 unaffected sibling-patient pairs were related; other patients and siblings were unrelated. ANCOVA analyses were used to examine 31P-MRS measures, with age and gender as covariates.
RESULTS: The phosphocreatine/adenosine triphosphate ratio was significantly reduced in both unaffected siblings and FEP patients, compared to controls. NAD+/NADH ratio was significantly reduced in patients compared to siblings and controls, with siblings showing a reduction in NAD+/NADH compared to controls that was not statistically significant. Compared to patients and controls, siblings showed significantly reduced levels of NAD+. Siblings did not differ from patients or controls on brain pH. DISCUSSION: Our results indicate that unaffected siblings show some, but not all the same abnormalities in brain energy metabolites and redox state as FEP patients. Thus, 31P-MRS studies may identify factors related both to risk and expression of psychosis.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  (31)P magnetic resonance spectroscopy; Bipolar disorder; Energy metabolism; Oxidative stress; Schizophrenia; Unaffected relatives

Mesh:

Substances:

Year:  2017        PMID: 28258794      PMCID: PMC5581291          DOI: 10.1016/j.schres.2017.02.024

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  40 in total

1.  31P-MR spectroscopy in monozygotic twins discordant for schizophrenia or schizoaffective disorder.

Authors:  Igor Nenadic; Kerstin Langbein; Matthias Weisbrod; Raka Maitra; Reinhard Rzanny; Alexander Gussew; Jürgen R Reichenbach; Heinrich Sauer; Stefan Smesny
Journal:  Schizophr Res       Date:  2011-11-03       Impact factor: 4.939

2.  Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy.

Authors:  J W Pettegrew; M S Keshavan; K Panchalingam; S Strychor; D B Kaplan; M G Tretta; M Allen
Journal:  Arch Gen Psychiatry       Date:  1991-06

3.  Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia.

Authors:  Stefan Smesny; Timm Rosburg; Igor Nenadic; Klaus Peter Fenk; Sebastian Kunstmann; Reinhardt Rzanny; Hans-Peter Volz; Heinrich Sauer
Journal:  Neuroimage       Date:  2006-12-29       Impact factor: 6.556

Review 4.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

Review 5.  Synthesis and transport of creatine in the CNS: importance for cerebral functions.

Authors:  Elidie Béard; Olivier Braissant
Journal:  J Neurochem       Date:  2010-08-25       Impact factor: 5.372

6.  In vivo evidence for cerebral bioenergetic abnormalities in schizophrenia measured using 31P magnetization transfer spectroscopy.

Authors:  Fei Du; Alissa J Cooper; Thida Thida; Selma Sehovic; Scott E Lukas; Bruce M Cohen; Xiaoliang Zhang; Dost Ongür
Journal:  JAMA Psychiatry       Date:  2014-01       Impact factor: 21.596

7.  Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives.

Authors:  Pawel Skudlarski; David J Schretlen; Gunvant K Thaker; Michael C Stevens; Matcheri S Keshavan; John A Sweeney; Carol A Tamminga; Brett A Clementz; Kasey O'Neil; Godfrey D Pearlson
Journal:  Am J Psychiatry       Date:  2013-08       Impact factor: 18.112

8.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

9.  An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy.

Authors:  J A Stanley; P C Williamson; D J Drost; T J Carr; R J Rylett; A Malla; R T Thompson
Journal:  Arch Gen Psychiatry       Date:  1995-05

10.  In vivo (31) P MRS assessment of intracellular NAD metabolites and NAD(+) /NADH redox state in human brain at 4 T.

Authors:  Ming Lu; Xiao-Hong Zhu; Wei Chen
Journal:  NMR Biomed       Date:  2016-06-03       Impact factor: 4.044

View more
  17 in total

Review 1.  The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson's disease and in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2019-12-17       Impact factor: 3.575

2.  Quantitative measurement of redox state in human brain by 31 P MRS at 7T with spectral simplification and inclusion of multiple nucleotide sugar components in data analysis.

Authors:  Jimin Ren; Craig R Malloy; A Dean Sherry
Journal:  Magn Reson Med       Date:  2020-05-09       Impact factor: 4.668

Review 3.  Does Neuroinflammation Underlie the Cognitive Changes Observed With Dietary Interventions?

Authors:  Jacqueline P Robbins; Egle Solito
Journal:  Front Neurosci       Date:  2022-05-10       Impact factor: 5.152

4.  Disrupted leptin-fatty acid biosynthesis is an early manifestation of metabolic abnormalities in schizophrenia.

Authors:  Mohammad M Khan
Journal:  World J Psychiatry       Date:  2022-06-19

Review 5.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

6.  Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies.

Authors:  Asli Ercan Dogan; Cagri Yuksel; Fei Du; Virginie-Anne Chouinard; Dost Öngür
Journal:  Neuropsychopharmacology       Date:  2018-03-14       Impact factor: 7.853

Review 7.  Mitochondria and Mood: Mitochondrial Dysfunction as a Key Player in the Manifestation of Depression.

Authors:  Josh Allen; Raquel Romay-Tallon; Kyle J Brymer; Hector J Caruncho; Lisa E Kalynchuk
Journal:  Front Neurosci       Date:  2018-06-06       Impact factor: 4.677

8.  Impaired insulin signaling in unaffected siblings and patients with first-episode psychosis.

Authors:  Virginie-Anne Chouinard; David C Henderson; Chiara Dalla Man; Linda Valeri; Brianna E Gray; Kyle P Ryan; Aaron M Cypess; Claudio Cobelli; Bruce M Cohen; Dost Öngür
Journal:  Mol Psychiatry       Date:  2018-03-09       Impact factor: 15.992

9.  Nutritional Ketosis Increases NAD+/NADH Ratio in Healthy Human Brain: An in Vivo Study by 31P-MRS.

Authors:  Lijing Xin; Özlem Ipek; Maurice Beaumont; Maya Shevlyakova; Nicolas Christinat; Mojgan Masoodi; Norman Greenberg; Rolf Gruetter; Bernard Cuenoud
Journal:  Front Nutr       Date:  2018-07-12

Review 10.  Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives.

Authors:  Evgeny A Ermakov; Elena M Dmitrieva; Daria A Parshukova; Daria V Kazantseva; Alisa R Vasilieva; Liudmila P Smirnova
Journal:  Oxid Med Cell Longev       Date:  2021-01-23       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.